WO2003002535A1 - Cyclic diamine compounds bearing six-membered cyclic groups - Google Patents
Cyclic diamine compounds bearing six-membered cyclic groups Download PDFInfo
- Publication number
- WO2003002535A1 WO2003002535A1 PCT/JP2002/006489 JP0206489W WO03002535A1 WO 2003002535 A1 WO2003002535 A1 WO 2003002535A1 JP 0206489 W JP0206489 W JP 0206489W WO 03002535 A1 WO03002535 A1 WO 03002535A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- trimethoxyphenyl
- synthesis
- yield
- title compound
- pyridine
- Prior art date
Links
- -1 Cyclic diamine compounds Chemical group 0.000 title claims abstract description 69
- 125000004122 cyclic group Chemical group 0.000 title description 2
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract description 42
- 239000002253 acid Substances 0.000 claims abstract description 25
- 150000003839 salts Chemical class 0.000 claims abstract description 20
- 230000021164 cell adhesion Effects 0.000 claims abstract description 17
- 230000008595 infiltration Effects 0.000 claims abstract description 16
- 238000001764 infiltration Methods 0.000 claims abstract description 16
- 208000006673 asthma Diseases 0.000 claims abstract description 9
- 206010003210 Arteriosclerosis Diseases 0.000 claims abstract description 8
- 208000011775 arteriosclerosis disease Diseases 0.000 claims abstract description 8
- 206010020751 Hypersensitivity Diseases 0.000 claims abstract description 7
- 208000026935 allergic disease Diseases 0.000 claims abstract description 7
- 230000007815 allergy Effects 0.000 claims abstract description 6
- 238000004519 manufacturing process Methods 0.000 claims description 89
- 239000000203 mixture Substances 0.000 claims description 39
- 239000003814 drug Substances 0.000 claims description 16
- 201000010099 disease Diseases 0.000 claims description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 10
- 206010061218 Inflammation Diseases 0.000 claims description 9
- 230000004054 inflammatory process Effects 0.000 claims description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 230000004709 cell invasion Effects 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 abstract description 115
- 230000002401 inhibitory effect Effects 0.000 abstract description 13
- 230000003449 preventive effect Effects 0.000 abstract description 2
- 229940126585 therapeutic drug Drugs 0.000 abstract description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 2
- 150000004677 hydrates Chemical class 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 90
- 230000015572 biosynthetic process Effects 0.000 description 88
- 238000003786 synthesis reaction Methods 0.000 description 88
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 45
- 125000005809 3,4,5-trimethoxyphenyl group Chemical group [H]C1=C(OC([H])([H])[H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 description 36
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 36
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 36
- 230000002829 reductive effect Effects 0.000 description 30
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 24
- 239000012458 free base Substances 0.000 description 24
- 239000000243 solution Substances 0.000 description 23
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 21
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 21
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 21
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 20
- 238000006243 chemical reaction Methods 0.000 description 19
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 19
- 235000002639 sodium chloride Nutrition 0.000 description 17
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 15
- 238000002360 preparation method Methods 0.000 description 15
- 238000010898 silica gel chromatography Methods 0.000 description 15
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 14
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 12
- 239000012044 organic layer Substances 0.000 description 12
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 11
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 10
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 10
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 10
- WVDDGKGOMKODPV-UHFFFAOYSA-N hydroxymethyl benzene Natural products OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 8
- 210000000265 leukocyte Anatomy 0.000 description 8
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 8
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 8
- 239000002585 base Substances 0.000 description 7
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 7
- 238000007796 conventional method Methods 0.000 description 7
- 239000000706 filtrate Substances 0.000 description 7
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- MTZQAGJQAFMTAQ-UHFFFAOYSA-N benzoic acid ethyl ester Natural products CCOC(=O)C1=CC=CC=C1 MTZQAGJQAFMTAQ-UHFFFAOYSA-N 0.000 description 6
- 239000000796 flavoring agent Substances 0.000 description 6
- 235000013355 food flavoring agent Nutrition 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- OKWNDHFPWXJEHM-UHFFFAOYSA-N 2-(3,4,5-trimethoxyphenyl)pyridine Chemical compound COC1=C(OC)C(OC)=CC(C=2N=CC=CC=2)=C1 OKWNDHFPWXJEHM-UHFFFAOYSA-N 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 5
- 239000012300 argon atmosphere Substances 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 5
- XBLVHTDFJBKJLG-UHFFFAOYSA-N nicotinic acid ethyl ester Natural products CCOC(=O)C1=CC=CN=C1 XBLVHTDFJBKJLG-UHFFFAOYSA-N 0.000 description 5
- 239000012453 solvate Substances 0.000 description 5
- 239000003381 stabilizer Substances 0.000 description 5
- 239000008107 starch Substances 0.000 description 5
- 235000019698 starch Nutrition 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- RULQUTYJXDLRFL-UHFFFAOYSA-N (3,4,5-trimethoxyphenyl)boronic acid Chemical compound COC1=CC(B(O)O)=CC(OC)=C1OC RULQUTYJXDLRFL-UHFFFAOYSA-N 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 4
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 108010008212 Integrin alpha4beta1 Proteins 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 description 4
- 102100023543 Vascular cell adhesion protein 1 Human genes 0.000 description 4
- 235000019445 benzyl alcohol Nutrition 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- HXITXNWTGFUOAU-UHFFFAOYSA-N dihydroxy-phenylborane Natural products OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 229910000027 potassium carbonate Inorganic materials 0.000 description 4
- JPJALAQPGMAKDF-UHFFFAOYSA-N selenium dioxide Chemical compound O=[Se]=O JPJALAQPGMAKDF-UHFFFAOYSA-N 0.000 description 4
- 229910052938 sodium sulfate Inorganic materials 0.000 description 4
- 235000011152 sodium sulphate Nutrition 0.000 description 4
- 210000003556 vascular endothelial cell Anatomy 0.000 description 4
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 3
- GNUTYFLMOHIJKQ-UHFFFAOYSA-N 5-[2-(chloromethyl)phenyl]-1,2,3-trimethoxybenzene Chemical compound COC1=C(OC)C(OC)=CC(C=2C(=CC=CC=2)CCl)=C1 GNUTYFLMOHIJKQ-UHFFFAOYSA-N 0.000 description 3
- DRVDQUYTYFCSRR-UHFFFAOYSA-N 5-[3-(chloromethyl)phenyl]-1,2,3-trimethoxybenzene Chemical compound COC1=C(OC)C(OC)=CC(C=2C=C(CCl)C=CC=2)=C1 DRVDQUYTYFCSRR-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 102100022339 Integrin alpha-L Human genes 0.000 description 3
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 3
- 102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 description 3
- 108010002352 Interleukin-1 Proteins 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 3
- 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 3
- 230000001464 adherent effect Effects 0.000 description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- YNHIGQDRGKUECZ-UHFFFAOYSA-N dichloropalladium;triphenylphosphanium Chemical compound Cl[Pd]Cl.C1=CC=CC=C1[PH+](C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1[PH+](C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-N 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 210000003979 eosinophil Anatomy 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 229940064982 ethylnicotinate Drugs 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 239000001530 fumaric acid Substances 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 230000002140 halogenating effect Effects 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 3
- FKRCODPIKNYEAC-UHFFFAOYSA-N propionic acid ethyl ester Natural products CCOC(=O)CC FKRCODPIKNYEAC-UHFFFAOYSA-N 0.000 description 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- LVPQCSPJDFBORZ-UHFFFAOYSA-N 1-oxido-4-(3,4,5-trimethoxyphenyl)pyridin-1-ium Chemical compound COC1=C(OC)C(OC)=CC(C=2C=C[N+]([O-])=CC=2)=C1 LVPQCSPJDFBORZ-UHFFFAOYSA-N 0.000 description 2
- FSQBTRGXDKQWCY-UHFFFAOYSA-N 2-(3,4,5-trimethoxyphenyl)pyrimidine Chemical compound COC1=C(OC)C(OC)=CC(C=2N=CC=CN=2)=C1 FSQBTRGXDKQWCY-UHFFFAOYSA-N 0.000 description 2
- PMNLUUOXGOOLSP-UHFFFAOYSA-N 2-mercaptopropanoic acid Chemical compound CC(S)C(O)=O PMNLUUOXGOOLSP-UHFFFAOYSA-N 0.000 description 2
- GIMCUKXDMWUBAY-UHFFFAOYSA-N 3-(chloromethyl)-2-(3,4,5-trimethoxyphenyl)pyridine Chemical compound COC1=C(OC)C(OC)=CC(C=2C(=CC=CN=2)CCl)=C1 GIMCUKXDMWUBAY-UHFFFAOYSA-N 0.000 description 2
- UPMRLMOBRSDTLI-UHFFFAOYSA-N 3-(chloromethyl)-5-(3,4,5-trimethoxyphenyl)pyridine Chemical compound COC1=C(OC)C(OC)=CC(C=2C=C(CCl)C=NC=2)=C1 UPMRLMOBRSDTLI-UHFFFAOYSA-N 0.000 description 2
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 2
- WEDZNLJCSJHUSX-UHFFFAOYSA-N 4-(chloromethyl)-6-(3,4,5-trimethoxyphenyl)pyrimidine Chemical compound COC1=C(OC)C(OC)=CC(C=2N=CN=C(CCl)C=2)=C1 WEDZNLJCSJHUSX-UHFFFAOYSA-N 0.000 description 2
- ULPLGNKBRLPZFE-UHFFFAOYSA-N 4-methyl-2-(3,4,5-trimethoxyphenyl)pyrimidine Chemical compound COC1=C(OC)C(OC)=CC(C=2N=C(C)C=CN=2)=C1 ULPLGNKBRLPZFE-UHFFFAOYSA-N 0.000 description 2
- LVILGAOSPDLNRM-UHFFFAOYSA-N 4-methylpyrimidine Chemical compound CC1=CC=NC=N1 LVILGAOSPDLNRM-UHFFFAOYSA-N 0.000 description 2
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 2
- ZKAHCAMZUKJNGV-UHFFFAOYSA-N 5-(chloromethyl)-2-(3,4,5-trimethoxyphenyl)pyridine Chemical compound COC1=C(OC)C(OC)=CC(C=2N=CC(CCl)=CC=2)=C1 ZKAHCAMZUKJNGV-UHFFFAOYSA-N 0.000 description 2
- QMDDTXWNUJXYDX-UHFFFAOYSA-N 5-[4-(chloromethyl)phenyl]-1,2,3-trimethoxybenzene Chemical compound COC1=C(OC)C(OC)=CC(C=2C=CC(CCl)=CC=2)=C1 QMDDTXWNUJXYDX-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- QVZCXCJXTMIDME-UHFFFAOYSA-N Biopropazepan Trimethoxybenzoate Chemical compound COC1=C(OC)C(OC)=CC(C(=O)OCCCN2CCN(CCCOC(=O)C=3C=C(OC)C(OC)=C(OC)C=3)CCC2)=C1 QVZCXCJXTMIDME-UHFFFAOYSA-N 0.000 description 2
- VLUCEYKETGOWEE-UHFFFAOYSA-N ClCC1=CCN(C=C1)C1=CC(=C(C(=C1)OC)OC)OC Chemical compound ClCC1=CCN(C=C1)C1=CC(=C(C(=C1)OC)OC)OC VLUCEYKETGOWEE-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- 108010024212 E-Selectin Proteins 0.000 description 2
- 102100023471 E-selectin Human genes 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- 239000007868 Raney catalyst Substances 0.000 description 2
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 2
- 229910000564 Raney nickel Inorganic materials 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- WSUIGZLIJCDHMT-UHFFFAOYSA-N [2-(3,4,5-trimethoxyphenyl)phenyl]methanol Chemical compound COC1=C(OC)C(OC)=CC(C=2C(=CC=CC=2)CO)=C1 WSUIGZLIJCDHMT-UHFFFAOYSA-N 0.000 description 2
- HXWUFXFGYHUGEF-UHFFFAOYSA-N [2-(3,4,5-trimethoxyphenyl)pyridin-4-yl]methanol Chemical compound COC1=C(OC)C(OC)=CC(C=2N=CC=C(CO)C=2)=C1 HXWUFXFGYHUGEF-UHFFFAOYSA-N 0.000 description 2
- RLLXUHDWIXFEFV-UHFFFAOYSA-N [2-[2-(3,4,5-trimethoxyphenyl)ethynyl]pyridin-4-yl]methanol Chemical compound COC1=C(OC)C(OC)=CC(C#CC=2N=CC=C(CO)C=2)=C1 RLLXUHDWIXFEFV-UHFFFAOYSA-N 0.000 description 2
- RVPYRKBXACZPTE-UHFFFAOYSA-N [2-methylsulfanyl-4-(3,4,5-trimethoxyphenyl)pyrimidin-5-yl]methanol Chemical compound COC1=C(OC)C(OC)=CC(C=2C(=CN=C(SC)N=2)CO)=C1 RVPYRKBXACZPTE-UHFFFAOYSA-N 0.000 description 2
- HLLAJAMEOFRTNP-UHFFFAOYSA-N [6-(3,4,5-trimethoxyphenyl)pyridin-3-yl]methanol Chemical compound COC1=C(OC)C(OC)=CC(C=2N=CC(CO)=CC=2)=C1 HLLAJAMEOFRTNP-UHFFFAOYSA-N 0.000 description 2
- CVEOFGBNRZVXMK-UHFFFAOYSA-N [6-(3,4,5-trimethoxyphenyl)pyrimidin-4-yl]methanol Chemical compound COC1=C(OC)C(OC)=CC(C=2N=CN=C(CO)C=2)=C1 CVEOFGBNRZVXMK-UHFFFAOYSA-N 0.000 description 2
- GOPYZMJAIPBUGX-UHFFFAOYSA-N [O-2].[O-2].[Mn+4] Chemical class [O-2].[O-2].[Mn+4] GOPYZMJAIPBUGX-UHFFFAOYSA-N 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- 125000005278 alkyl sulfonyloxy group Chemical group 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 230000000879 anti-atherosclerotic effect Effects 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 description 2
- 239000000043 antiallergic agent Substances 0.000 description 2
- 239000000924 antiasthmatic agent Substances 0.000 description 2
- 239000003435 antirheumatic agent Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 125000005279 aryl sulfonyloxy group Chemical group 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 235000010216 calcium carbonate Nutrition 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 125000001309 chloro group Chemical group Cl* 0.000 description 2
- 206010009887 colitis Diseases 0.000 description 2
- 229960001079 dilazep Drugs 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- IGRLNCOFYMWKBU-UHFFFAOYSA-N ethyl 2-chloropyridine-4-carboxylate Chemical compound CCOC(=O)C1=CC=NC(Cl)=C1 IGRLNCOFYMWKBU-UHFFFAOYSA-N 0.000 description 2
- 239000003889 eye drop Substances 0.000 description 2
- 229940012356 eye drops Drugs 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 239000007951 isotonicity adjuster Substances 0.000 description 2
- 239000012280 lithium aluminium hydride Substances 0.000 description 2
- 239000003589 local anesthetic agent Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000011976 maleic acid Substances 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000007923 nasal drop Substances 0.000 description 2
- 229940100662 nasal drops Drugs 0.000 description 2
- 235000001968 nicotinic acid Nutrition 0.000 description 2
- 239000011664 nicotinic acid Substances 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 239000012279 sodium borohydride Substances 0.000 description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 description 2
- JHJLBTNAGRQEKS-UHFFFAOYSA-M sodium bromide Chemical compound [Na+].[Br-] JHJLBTNAGRQEKS-UHFFFAOYSA-M 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- CWERGRDVMFNCDR-UHFFFAOYSA-N thioglycolic acid Chemical compound OC(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-N 0.000 description 2
- FSJPQPQXDUGPFV-UHFFFAOYSA-N (2-ethoxy-2-oxoethyl)phosphonic acid Chemical compound CCOC(=O)CP(O)(O)=O FSJPQPQXDUGPFV-UHFFFAOYSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 1
- ZQNZEFHEJGVBGW-UHFFFAOYSA-N 1,4-bis[3-[2-(3,4,5-trimethoxyphenyl)pyridin-4-yl]propyl]piperazine Chemical compound COC1=C(OC)C(OC)=CC(C=2N=CC=C(CCCN3CCN(CCCC=4C=C(N=CC=4)C=4C=C(OC)C(OC)=C(OC)C=4)CC3)C=2)=C1 ZQNZEFHEJGVBGW-UHFFFAOYSA-N 0.000 description 1
- LZCUSDGSVSPMPA-UHFFFAOYSA-N 1,4-bis[[2-(3,4,5-trimethoxyphenyl)phenyl]methyl]piperazine;dihydrochloride Chemical compound Cl.Cl.COC1=C(OC)C(OC)=CC(C=2C(=CC=CC=2)CN2CCN(CC=3C(=CC=CC=3)C=3C=C(OC)C(OC)=C(OC)C=3)CC2)=C1 LZCUSDGSVSPMPA-UHFFFAOYSA-N 0.000 description 1
- PAWCZQFQLRQHAR-UHFFFAOYSA-N 1,4-bis[[3-(3,4,5-trimethoxyphenyl)phenyl]methyl]-1,4-diazepane Chemical compound COC1=C(OC)C(OC)=CC(C=2C=C(CN3CCN(CC=4C=C(C=CC=4)C=4C=C(OC)C(OC)=C(OC)C=4)CCC3)C=CC=2)=C1 PAWCZQFQLRQHAR-UHFFFAOYSA-N 0.000 description 1
- HTHAQEBOCJHBJD-UHFFFAOYSA-N 1,4-bis[[3-(3,4,5-trimethoxyphenyl)phenyl]methyl]piperazine Chemical compound COC1=C(OC)C(OC)=CC(C=2C=C(CN3CCN(CC=4C=C(C=CC=4)C=4C=C(OC)C(OC)=C(OC)C=4)CC3)C=CC=2)=C1 HTHAQEBOCJHBJD-UHFFFAOYSA-N 0.000 description 1
- LCHNUVFGINJNKB-UHFFFAOYSA-N 1,4-bis[[6-(3,4,5-trimethoxyphenyl)pyridin-3-yl]methyl]-1,4-diazepane Chemical compound COC1=C(OC)C(OC)=CC(C=2N=CC(CN3CCN(CC=4C=NC(=CC=4)C=4C=C(OC)C(OC)=C(OC)C=4)CCC3)=CC=2)=C1 LCHNUVFGINJNKB-UHFFFAOYSA-N 0.000 description 1
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical class C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- OKAHFPIZPJMVRQ-UHFFFAOYSA-N 2-(3,4,5-trimethoxyphenyl)pyridine-4-carbaldehyde Chemical compound COC1=C(OC)C(OC)=CC(C=2N=CC=C(C=O)C=2)=C1 OKAHFPIZPJMVRQ-UHFFFAOYSA-N 0.000 description 1
- JZPMURBXEAZWAI-UHFFFAOYSA-N 2-(chloromethyl)-4-(3,4,5-trimethoxyphenyl)pyridine Chemical compound COC1=C(OC)C(OC)=CC(C=2C=C(CCl)N=CC=2)=C1 JZPMURBXEAZWAI-UHFFFAOYSA-N 0.000 description 1
- PDDZGTPHJJDAMJ-UHFFFAOYSA-N 2-(chloromethyl)-6-(3,4,5-trimethoxyphenyl)pyridine Chemical compound COC1=C(OC)C(OC)=CC(C=2N=C(CCl)C=CC=2)=C1 PDDZGTPHJJDAMJ-UHFFFAOYSA-N 0.000 description 1
- GHCFWKFREBNSPC-UHFFFAOYSA-N 2-Amino-4-methylpyrimidine Chemical compound CC1=CC=NC(N)=N1 GHCFWKFREBNSPC-UHFFFAOYSA-N 0.000 description 1
- NHWREYUVZRWPSI-UHFFFAOYSA-N 2-[2-(3,4,5-trimethoxyphenyl)ethynyl]pyridine-4-carboxylic acid Chemical compound COC1=C(OC)C(OC)=CC(C#CC=2N=CC=C(C=2)C(O)=O)=C1 NHWREYUVZRWPSI-UHFFFAOYSA-N 0.000 description 1
- LLBKEUTWJFQRJU-UHFFFAOYSA-N 2-[4-(4-aminophenyl)sulfonylanilino]ethanol Chemical group C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(NCCO)C=C1 LLBKEUTWJFQRJU-UHFFFAOYSA-N 0.000 description 1
- UZIJEBOLOXOVFY-UHFFFAOYSA-N 2-bromo-4-methylpyrimidine Chemical compound CC1=CC=NC(Br)=N1 UZIJEBOLOXOVFY-UHFFFAOYSA-N 0.000 description 1
- ZSLUVFAKFWKJRC-IGMARMGPSA-N 232Th Chemical compound [232Th] ZSLUVFAKFWKJRC-IGMARMGPSA-N 0.000 description 1
- TVZRAEYQIKYCPH-UHFFFAOYSA-N 3-(trimethylsilyl)propane-1-sulfonic acid Chemical compound C[Si](C)(C)CCCS(O)(=O)=O TVZRAEYQIKYCPH-UHFFFAOYSA-N 0.000 description 1
- NLQRRMXSOJQERA-UHFFFAOYSA-N 3-[2-(3,4,5-trimethoxyphenyl)pyridin-3-yl]propan-1-ol Chemical compound COC1=C(OC)C(OC)=CC(C=2C(=CC=CN=2)CCCO)=C1 NLQRRMXSOJQERA-UHFFFAOYSA-N 0.000 description 1
- GBVMEMRPHADANS-UHFFFAOYSA-N 3-[2-(3,4,5-trimethoxyphenyl)pyridin-3-yl]propyl methanesulfonate Chemical compound COC1=C(OC)C(OC)=CC(C=2C(=CC=CN=2)CCCOS(C)(=O)=O)=C1 GBVMEMRPHADANS-UHFFFAOYSA-N 0.000 description 1
- CSRMLOUXRNDLPV-UHFFFAOYSA-N 3-[2-(3,4,5-trimethoxyphenyl)pyridin-4-yl]propan-1-ol Chemical compound COC1=C(OC)C(OC)=CC(C=2N=CC=C(CCCO)C=2)=C1 CSRMLOUXRNDLPV-UHFFFAOYSA-N 0.000 description 1
- PXROMBPCGYKIGA-UHFFFAOYSA-N 3-[2-(3,4,5-trimethoxyphenyl)pyridin-4-yl]propyl methanesulfonate Chemical compound COC1=C(OC)C(OC)=CC(C=2N=CC=C(CCCOS(C)(=O)=O)C=2)=C1 PXROMBPCGYKIGA-UHFFFAOYSA-N 0.000 description 1
- MZSAMHOCTRNOIZ-UHFFFAOYSA-N 3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-phenylaniline Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(NC2=CC=CC=C2)C=CC=1 MZSAMHOCTRNOIZ-UHFFFAOYSA-N 0.000 description 1
- QOXOZONBQWIKDA-UHFFFAOYSA-N 3-hydroxypropyl Chemical group [CH2]CCO QOXOZONBQWIKDA-UHFFFAOYSA-N 0.000 description 1
- DJVIUJCWCBEVMD-UHFFFAOYSA-N 3-methyl-1,2-dihydropyrimidin-6-one Chemical compound CN1CNC(=O)C=C1 DJVIUJCWCBEVMD-UHFFFAOYSA-N 0.000 description 1
- YBFWOTYPJZJSDJ-UHFFFAOYSA-N 4-(3,4,5-trimethoxyphenyl)pyridine Chemical compound COC=1C=C(C=C(C=1OC)OC)C1=CC=NC=C1 YBFWOTYPJZJSDJ-UHFFFAOYSA-N 0.000 description 1
- SBGHNDCBGPREJJ-UHFFFAOYSA-N 4-(chloromethyl)-2-(3,4,5-trimethoxyphenyl)pyridine Chemical compound COC1=C(OC)C(OC)=CC(C=2N=CC=C(CCl)C=2)=C1 SBGHNDCBGPREJJ-UHFFFAOYSA-N 0.000 description 1
- OQGFIZPHTCLDNE-UHFFFAOYSA-N 4-(chloromethyl)-2-(3,4,5-trimethoxyphenyl)pyrimidine Chemical compound COC1=C(OC)C(OC)=CC(C=2N=C(CCl)C=CN=2)=C1 OQGFIZPHTCLDNE-UHFFFAOYSA-N 0.000 description 1
- ZVZZCBVUXJKPRX-UHFFFAOYSA-N 4-(chloromethyl)-2-[2-(3,4,5-trimethoxyphenyl)ethynyl]pyridine Chemical compound COC1=C(OC)C(OC)=CC(C#CC=2N=CC=C(CCl)C=2)=C1 ZVZZCBVUXJKPRX-UHFFFAOYSA-N 0.000 description 1
- ZRXLKDCFWJECNO-UHFFFAOYSA-N 4-bromo-1-oxidopyridin-1-ium Chemical compound [O-][N+]1=CC=C(Br)C=C1 ZRXLKDCFWJECNO-UHFFFAOYSA-N 0.000 description 1
- MPZMVUQGXAOJIK-UHFFFAOYSA-N 4-bromopyridine;hydron;chloride Chemical compound Cl.BrC1=CC=NC=C1 MPZMVUQGXAOJIK-UHFFFAOYSA-N 0.000 description 1
- MVAXKFAQKTWRAH-UHFFFAOYSA-N 4-chloro-6-methylpyrimidine Chemical compound CC1=CC(Cl)=NC=N1 MVAXKFAQKTWRAH-UHFFFAOYSA-N 0.000 description 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- YXFOYYHPDMJAEV-UHFFFAOYSA-N 5-(chloromethyl)-4-(3,4,5-trimethoxyphenyl)pyrimidine Chemical compound COC1=C(OC)C(OC)=CC(C=2C(=CN=CN=2)CCl)=C1 YXFOYYHPDMJAEV-UHFFFAOYSA-N 0.000 description 1
- LPMDFSVPSBSRSV-UHFFFAOYSA-N 5-[chloro(phenyl)methyl]-1,2,3-trimethoxybenzene Chemical compound COC1=C(OC)C(OC)=CC(C(Cl)C=2C=CC=CC=2)=C1 LPMDFSVPSBSRSV-UHFFFAOYSA-N 0.000 description 1
- CDZJQFRCCCDJLD-UHFFFAOYSA-N 5-ethynyl-1,2,3-trimethoxybenzene Chemical group COC1=CC(C#C)=CC(OC)=C1OC CDZJQFRCCCDJLD-UHFFFAOYSA-N 0.000 description 1
- CQVUHGXTMUIACI-UHFFFAOYSA-N 6-(3,4,5-trimethoxyphenyl)pyrimidine-4-carbaldehyde Chemical compound COC1=C(OC)C(OC)=CC(C=2N=CN=C(C=O)C=2)=C1 CQVUHGXTMUIACI-UHFFFAOYSA-N 0.000 description 1
- LHRIUKSRPHFASO-UHFFFAOYSA-N 6-methyl-1h-pyrimidin-4-one Chemical compound CC1=CC(=O)N=CN1 LHRIUKSRPHFASO-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 208000031873 Animal Disease Models Diseases 0.000 description 1
- 244000105975 Antidesma platyphyllum Species 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 102100032912 CD44 antigen Human genes 0.000 description 1
- 101100289995 Caenorhabditis elegans mac-1 gene Proteins 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- XHIMNYDJNLUMFZ-UHFFFAOYSA-N ClCC=1C=NCN(C1)C1=CC(=C(C(=C1)OC)OC)OC Chemical compound ClCC=1C=NCN(C1)C1=CC(=C(C(=C1)OC)OC)OC XHIMNYDJNLUMFZ-UHFFFAOYSA-N 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 description 1
- 229920001076 Cutan Polymers 0.000 description 1
- 229920000832 Cutin Polymers 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 208000009386 Experimental Arthritis Diseases 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 229910021586 Nickel(II) chloride Inorganic materials 0.000 description 1
- RHKCJTBWUXPISS-UHFFFAOYSA-N OCC1=CCN(C=C1)C1=CC(=C(C(=C1)OC)OC)OC Chemical compound OCC1=CCN(C=C1)C1=CC(=C(C(=C1)OC)OC)OC RHKCJTBWUXPISS-UHFFFAOYSA-N 0.000 description 1
- LZWILKDDEWACKW-UHFFFAOYSA-N OCC=1CN(C=CC1)C1=CC(=C(C(=C1)OC)OC)OC Chemical compound OCC=1CN(C=CC1)C1=CC(=C(C(=C1)OC)OC)OC LZWILKDDEWACKW-UHFFFAOYSA-N 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 102000008212 P-Selectin Human genes 0.000 description 1
- 108010035766 P-Selectin Proteins 0.000 description 1
- 101150092610 PKH2 gene Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Natural products C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 1
- 108090000184 Selectins Proteins 0.000 description 1
- 102000003800 Selectins Human genes 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 108700012920 TNF Proteins 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 229910052776 Thorium Inorganic materials 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- DIFXMCRMEAIFGF-UHFFFAOYSA-N [4-(3,4,5-trimethoxyphenyl)pyrimidin-5-yl]methanol Chemical compound COC1=C(OC)C(OC)=CC(C=2C(=CN=CN=2)CO)=C1 DIFXMCRMEAIFGF-UHFFFAOYSA-N 0.000 description 1
- WVEKRSMKRXFFSB-UHFFFAOYSA-N [5-(3,4,5-trimethoxyphenyl)pyridin-3-yl]methanol Chemical compound COC1=C(OC)C(OC)=CC(C=2C=C(CO)C=NC=2)=C1 WVEKRSMKRXFFSB-UHFFFAOYSA-N 0.000 description 1
- KSKXIWFTJDQKNI-UHFFFAOYSA-N [6-(3,4,5-trimethoxyphenyl)pyridin-2-yl]methanol Chemical compound COC1=C(OC)C(OC)=CC(C=2N=C(CO)C=CC=2)=C1 KSKXIWFTJDQKNI-UHFFFAOYSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 208000002205 allergic conjunctivitis Diseases 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 238000011558 animal model by disease Methods 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000001088 anti-asthma Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000003356 anti-rheumatic effect Effects 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 208000024998 atopic conjunctivitis Diseases 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- QSKWJTXWJJOJFP-UHFFFAOYSA-N chloroform;ethoxyethane Chemical compound ClC(Cl)Cl.CCOCC QSKWJTXWJJOJFP-UHFFFAOYSA-N 0.000 description 1
- OQNGCCWBHLEQFN-UHFFFAOYSA-N chloroform;hexane Chemical compound ClC(Cl)Cl.CCCCCC OQNGCCWBHLEQFN-UHFFFAOYSA-N 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000006482 condensation reaction Methods 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- GBRBMTNGQBKBQE-UHFFFAOYSA-L copper;diiodide Chemical compound I[Cu]I GBRBMTNGQBKBQE-UHFFFAOYSA-L 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- RCJVRSBWZCNNQT-UHFFFAOYSA-N dichloridooxygen Chemical compound ClOCl RCJVRSBWZCNNQT-UHFFFAOYSA-N 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 210000003989 endothelium vascular Anatomy 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- BIHHBTVQFPVSTE-UHFFFAOYSA-N ethyl 2-bromobenzoate Chemical compound CCOC(=O)C1=CC=CC=C1Br BIHHBTVQFPVSTE-UHFFFAOYSA-N 0.000 description 1
- QAUASTLEZAPQTB-UHFFFAOYSA-N ethyl 3-bromobenzoate Chemical compound CCOC(=O)C1=CC=CC(Br)=C1 QAUASTLEZAPQTB-UHFFFAOYSA-N 0.000 description 1
- BRQKCIDXEIXJKI-UHFFFAOYSA-N ethyl 5-(3,4,5-trimethoxyphenyl)pyridine-3-carboxylate Chemical compound CCOC(=O)C1=CN=CC(C=2C=C(OC)C(OC)=C(OC)C=2)=C1 BRQKCIDXEIXJKI-UHFFFAOYSA-N 0.000 description 1
- PCPIANOJERKFJI-UHFFFAOYSA-N ethyl 5-bromopyridine-3-carboxylate Chemical compound CCOC(=O)C1=CN=CC(Br)=C1 PCPIANOJERKFJI-UHFFFAOYSA-N 0.000 description 1
- AQXJQPGSQVERQB-UHFFFAOYSA-N ethyl 6-(3,4,5-trimethoxyphenyl)pyridine-2-carboxylate Chemical compound CCOC(=O)C1=CC=CC(C=2C=C(OC)C(OC)=C(OC)C=2)=N1 AQXJQPGSQVERQB-UHFFFAOYSA-N 0.000 description 1
- KPLWFBKXDUBNLL-UHFFFAOYSA-N ethyl 6-(3,4,5-trimethoxyphenyl)pyridine-3-carboxylate Chemical compound N1=CC(C(=O)OCC)=CC=C1C1=CC(OC)=C(OC)C(OC)=C1 KPLWFBKXDUBNLL-UHFFFAOYSA-N 0.000 description 1
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 1
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229940043351 ethyl-p-hydroxybenzoate Drugs 0.000 description 1
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 1
- JIGKNQYAXRFTKD-UHFFFAOYSA-N ethynyl pyridine-3-carboxylate Chemical compound C#COC(=O)C1=CC=CN=C1 JIGKNQYAXRFTKD-UHFFFAOYSA-N 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 235000009424 haa Nutrition 0.000 description 1
- 230000026030 halogenation Effects 0.000 description 1
- 238000005658 halogenation reaction Methods 0.000 description 1
- 210000003701 histiocyte Anatomy 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 239000001341 hydroxy propyl starch Substances 0.000 description 1
- 150000005419 hydroxybenzoic acid derivatives Chemical class 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000013828 hydroxypropyl starch Nutrition 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 229960004393 lidocaine hydrochloride Drugs 0.000 description 1
- YECIFGHRMFEPJK-UHFFFAOYSA-N lidocaine hydrochloride monohydrate Chemical compound O.[Cl-].CC[NH+](CC)CC(=O)NC1=C(C)C=CC=C1C YECIFGHRMFEPJK-UHFFFAOYSA-N 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 125000005948 methanesulfonyloxy group Chemical group 0.000 description 1
- PEUKABHPDWHYEB-UHFFFAOYSA-N methyl 4-(3,4,5-trimethoxyphenyl)pyridine-2-carboxylate Chemical compound C1=NC(C(=O)OC)=CC(C=2C=C(OC)C(OC)=C(OC)C=2)=C1 PEUKABHPDWHYEB-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 125000004957 naphthylene group Chemical group 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- QMMRZOWCJAIUJA-UHFFFAOYSA-L nickel dichloride Chemical compound Cl[Ni]Cl QMMRZOWCJAIUJA-UHFFFAOYSA-L 0.000 description 1
- 229940100688 oral solution Drugs 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- AAEVYOVXGOFMJO-UHFFFAOYSA-N prometryn Chemical compound CSC1=NC(NC(C)C)=NC(NC(C)C)=N1 AAEVYOVXGOFMJO-UHFFFAOYSA-N 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 235000020374 simple syrup Nutrition 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 235000010288 sodium nitrite Nutrition 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000004328 sodium tetraborate Substances 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 230000006103 sulfonylation Effects 0.000 description 1
- 238000005694 sulfonylation reaction Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000001258 synovial membrane Anatomy 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 210000003606 umbilical vein Anatomy 0.000 description 1
- 235000012141 vanillin Nutrition 0.000 description 1
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 1
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
Definitions
- Cyclic diamine compounds having a hame cyclic group having a hame cyclic group
- the present invention provides a cyclic diamine compound which has a cell adhesion inhibitory action and a cell infiltration inhibitory action and is useful as an anti-asthmatic agent, an anti-allergy agent, an anti-rheumatic agent, an anti-arteriosclerosis agent, an anti-inflammatory agent
- the present invention relates to a salt thereof and a pharmaceutical field containing the salt.
- Leukocytes in the activated bloodstream adhere to vascular endothelial cells via an interaction called a roll ring or tethering with the activated vascular endothelial cells as well. adhe si on) Thereafter, it infiltrates the vascular endothelium (tran smi gration) and infiltrates the site of inflammation (Springer TA. Et al., Annu. Rev. Phy sio 1.57, 827-872 (1995)).
- the adhesion between leukocytes and vascular endothelial cells is achieved by the immunoglobulin superfamily (ICAM-1, VCAM-1, etc.) and the selectin family (E-selectin, etc.) which are expressed on the cell surface by stimulation with cytokines.
- IMM-1, VCAM-1, etc. immunoglobulin superfamily
- E-selectin, etc. selectin family
- Integrin family LFA-1, VLA-4, etc.
- various cell adhesion molecules such as CD44 play important roles (Clinical Immunity, 30, Supp 1.18 (1998)). It has been pointed out that this is related to enhanced expression of the molecule.
- drugs that can inhibit adhesion via cell adhesion molecules include allergic diseases such as bronchial asthma, dermatitis, rhinitis and conjunctivitis, rheumatoid arthritis, nephritis, inflammatory bowel disease, diabetes, and atherosclerosis. It is considered to be effective as a prophylactic and therapeutic agent for autoimmune diseases such as those and chronic inflammatory diseases.
- autoimmune diseases such as those and chronic inflammatory diseases.
- antibodies against leukocyte-side cell adhesion molecules such as LFA-1, Mac-1 and VLA-4 or their ligands such as ICAM-1, VCAM-1, P-selectin, and E-selectin on vascular endothelial cells.
- an antibody against cutin or the like suppresses infiltration of leukocytes into local inflammation in various animal disease models.
- neutralizing antibodies against VCAM-1 and its counterpart receptor VLA-4 can delay the onset of diabetes in a NOD mouse model that spontaneously develops diabetes (Michie S A. et al., Curr Top. Micr ob iol. Immu no 1. 231, 65-83 (1998)).
- antibodies against VLA-4 or ICAM-1 and its counterpart LFA-1 inhibit eosinophil infiltration in guinea pig or mouse allergic conjunctivitis models (Ebihara et al., Currrent Eye Reagent). s. 19,20-25 (1999), Whitcup SM.
- mice deficient in these cell adhesion molecules suppression of infiltration of leukocytes into inflamed tissues is observed as in the test of the inflammation model (Bend jell ouhl F. et al., Clin. E p.Immu no 1.119, 57-63 (2000), Wo 1 yniec WW. Et al., Am. J. Respir. Cell Mo 1. Biol. 18, 777-785 (1998), Bu ilard DC. et al., J. Immuno 1.157, 3153-3158 (1996)).
- an object of the present invention is to provide a substance which has cell adhesion and cell invasion inhibitory actions, and further has excellent anti-asthmatic action, anti-allergic action, anti-rheumatic action, anti-atherosclerotic action and anti-inflammatory action. And Disclosure of the invention
- the present inventors have conducted intensive studies to obtain a substance that inhibits cell adhesion and cell invasion.
- the compound represented by the following general formula (1) has an excellent cell adhesion inhibiting action. It has a cell invasion inhibitory effect and is useful as an anti-allergic agent, an anti-asthmatic agent, an anti-rheumatic agent, an anti-atherosclerotic agent, and an anti-inflammatory agent, and completed the present invention.
- A represents a single bond or C ⁇ C;
- X and Y each independently represent CH or a nitrogen atom;
- m represents a number of 1 or 2;
- n represents a number of 1 to 5 ]
- the present invention also provides a medicine containing the above cyclic diamine compound, an acid addition salt thereof or a hydrate thereof as an active ingredient.
- the present invention further provides a pharmaceutical composition comprising the above-mentioned cyclic diamine compound, an acid addition salt thereof or a hydrate thereof, and a pharmaceutically acceptable carrier. Further, the present invention provides the use of the above-mentioned cyclic diamine compound, an acid addition salt thereof or a hydrate thereof for the production of a medicament.
- the present invention is characterized in that an effective amount of the above-mentioned cyclic diamine compound, an acid addition salt thereof or a hydrate thereof is administered to a patient in need of treatment, and is characterized by cell adhesion and Z or cell infiltration.
- the present invention provides a method for treating a disease.
- A represents a single bond or C ⁇ C.
- X and Y each represent a CH or a nitrogen atom.
- the ring containing X and Y is a benzene, pyridine or pyrimidine ring.
- m represents 1 or 2
- n represents a number of 1 to 5
- n is preferably a number of 1 to 3.
- the acid addition salt of the compound (1) of the present invention is not particularly limited as long as it is a pharmaceutically acceptable salt.
- examples thereof include hydrochloride, hydrobromide, hydroiodide, sulfate, and phosphate.
- Acid addition salts of mineral acids such as benzoate, methanesulfonate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate, oxalate, maleate, fumarate, Acid addition salts of organic acids such as tartrate, citrate and acetate can be mentioned.
- the compound (1) of the present invention may exist in the form of a solvate represented by a hydrate, and the solvate is also included in the present invention.
- the compound (1) of the present invention can be produced, for example, according to the following reaction formula.
- R 1 represents a hydrogen atom or a lower alkyl group
- R 2 represents a halogen atom, an alkylsulfonyloxy group or an arylsulfonyloxy group
- A, X, Y, m and n are as defined above. the same]
- the compound (1) of the present invention can be obtained by condensing a cyclic diamine.
- Examples of the halogen atom represented by R 2 include a chlorine atom and a bromine atom.
- Examples of the alkylsulfonyloxy group include a methanesulfonyloxy group, and examples of the arylsulfonyloxy group include a p-toluenesulfonyloxy group.
- the reduction reaction of the carboxylic acid (2) or the aldehyde compound (3) is carried out, for example, in a tetrahydrofuran (THF) at room temperature, preferably at 0 ° C. to room temperature, at a reducing agent such as lithium aluminum hydride. The reaction is carried out for several seconds to several hours, preferably for 30 minutes, in the presence of.
- THF tetrahydrofuran
- halogenating agent used for halogenating the alcohol (4) examples include thionyl chloride.
- methanesulfonyl chloride and the like are used as alkylsulfonylating agents, and p-toluenesulfonyl chloride and the like are used as arylsulfonylating agents.
- a solvent such as chloroform, dichloromethane, ethyl acetate, ether, THF, dioxane, etc.
- the alcohol compound (4) can be prepared by converting the alcohol (4) in the presence of a base such as triethylamine or pyridin in the form of chloroform, dichloromethane, ethyl acetate, ether, HF, dioxane, pyridine or the like.
- a base such as triethylamine or pyridin in the form of chloroform, dichloromethane, ethyl acetate, ether, HF, dioxane, pyridine or the like.
- the reaction is carried out by stirring in a solvent at a temperature of more than 120 to room temperature, preferably 0 to room temperature, for 1 hour to several days, preferably for 5 hours.
- the condensation reaction of compound (5) with cyclic diamine is carried out in a solvent such as N, N-dimethylformamide (DMF), dimethylsulfoxide (DMSO), and acetonitrile in the presence of a base such as potassium carbonate at room temperature.
- a solvent such as N, N-dimethylformamide (DMF), dimethylsulfoxide (DMSO), and acetonitrile
- the stirring is carried out at 0, preferably 50, for 1 hour to several days, preferably 5 hours.
- the compound (1) of the present invention can be obtained by the above-mentioned method, and can be further purified, if necessary, by a conventional purification means such as a recrystallization method and column chromatography. If necessary, the desired salt or solvate can be prepared by a conventional method.
- the thus-obtained compound (1) of the present invention exhibits an excellent cell adhesion inhibitory action as shown in Examples described later, and exhibits asthma, arregii, rheumatism in animals including humans. It is useful as a medicament for treating or preventing arteriosclerosis, inflammation and the like.
- the medicament of the present invention comprises the compound (1), a salt thereof or a solvate thereof as an active ingredient.
- the dosage form is not particularly limited and can be appropriately selected depending on the purpose of treatment. Examples of the dosage form include oral preparations, injections, suppositories, ointments, inhalants, eye drops, nasal drops, and patches. These dosage forms can be produced by mixing a pharmaceutically acceptable carrier and using a conventional formulation method known to those skilled in the art.
- the compound (1) of the present invention is usually treated with excipients and, if necessary, a binder, a disintegrant, a lubricant, a coloring agent, a flavoring agent, a flavoring agent, and the like. Tablets, coated tablets, granules, powders, capsules, etc. can be produced by the method.
- Such additives may be those commonly used in the art, such as lactose, sucrose, sodium chloride, glucose, starch, calcium carbonate, kaolin, microcrystalline cellulose.
- the flavoring agent include sucrose, orange peel, citric acid, tartaric acid and the like.
- a flavoring agent, a buffer, a stabilizing agent, a flavoring agent, etc. are added to the compound (1) of the present invention to produce an oral solution, a syrup, an elixir, etc. in a conventional manner.
- vanillin or the like can be used as a flavoring agent
- sodium citrate or the like can be used as a buffer
- tragacanth, gum arabic, or gelatin can be used as a stabilizer.
- a PH regulator, a buffer, a stabilizing agent, an isotonic agent, a local anesthetic, etc. are added to the compound of the present invention (1), and a subcutaneous, intramuscular or intravenous injection is prepared by a conventional method.
- pH adjuster and buffer were sodium citrate.
- the stabilizer include sodium pyrosulfite, EDTA, thioglycolic acid, thiolactic acid and the like.
- Local anesthetics include proforce hydrochloride, lidocaine hydrochloride and the like.
- the isotonic agent include sodium chloride, glucose and the like.
- the compound (1) of the present invention may be formulated with a pharmaceutical carrier known in the art, for example, polyethylene glycol, lanolin, cocoa butter, fatty acid triglyceride, and, if necessary, Tween (registered trademark). After adding a surfactant such as described above, it can be produced by a conventional method.
- a pharmaceutical carrier known in the art, for example, polyethylene glycol, lanolin, cocoa butter, fatty acid triglyceride, and, if necessary, Tween (registered trademark).
- a base, a stabilizer, a wetting agent, a preservative and the like usually used for the compound (1) of the present invention are blended as required, and mixed and formulated by a conventional method.
- the base include liquid paraffin, white petrolatum, beeswax, octyldodecyl alcohol, paraffin and the like.
- the preservative include methyl p-hydroxybenzoate, ethyl p-hydroxybenzoate, propyl p-hydroxybenzoate and the like.
- inhalants In addition to the above, inhalants, eye drops, and nasal drops can be prepared by conventional methods.
- the dosage of the medicament of the present invention varies depending on age, body weight, symptoms, administration form, number of administrations, and the like.
- the amount of the compound of the present invention (1) is 1 to 100 mg / day for an adult. Is preferably orally or parenterally administered once or divided into several times.
- Nickel chloride (3.0 mg) was added to THF (1 mL) under an argon atmosphere.
- a solution of 0.93M-bromomethylmagnesium in THF (0.38 mL) was slowly added dropwise, and then 2_chloro mouth_4- (3,4,5-trimethoxyphenyl) pyridine (5 Omg) in THF (5 mg) was added. 2 mL) solution was slowly added dropwise. After stirring for 10 minutes at 0, the mixture was stirred at 70 for 1.5 hours. At 0, a small amount of dilute hydrochloric acid was added, and the mixture was diluted with ethyl acetate.
- the method was performed by referring to the method of Ross et al. (J. Biol. Chem., 267, 8537-8543 (1992)). That is, blood vessels derived from human umbilical vein Endothelial cells (HUVEC) are confluent in a 48-well plate (after culturing until complete,
- UUVEC umbilical vein Endothelial cells
- U937 which is a cell derived from human monocyte Z histiocyte fluorescently labeled with PKH2 (Dainippon Pharmaceutical Co., Ltd.), were added to each well. After standing at room temperature for 1 hour, unadhered U937 was washed out, the cells were lysed with l% Triton X-100, and the remaining fluorescence intensity was measured (excitation wavelength 485 nm, measurement wavelength 530 nm).
- HUVEC is EGM—
- the compound (1) of the present invention has an excellent inhibitory action on cell adhesion and cell invasion, and is useful as a preventive or therapeutic drug for allergy, asthma, rheumatism, arteriosclerosis, inflammatory disease and the like.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyridine Compounds (AREA)
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE60209904T DE60209904T2 (de) | 2001-06-29 | 2002-06-27 | Cyclische diaminverbindung mit 6-gliedrigen ringgruppen |
JP2003508916A JP4235103B2 (ja) | 2001-06-29 | 2002-06-27 | 六員環式基を有する環状ジアミン化合物 |
EP02736188A EP1403249B1 (en) | 2001-06-29 | 2002-06-27 | Cyclic diamine compounds bearing six-membered cyclic groups |
CA2451240A CA2451240C (en) | 2001-06-29 | 2002-06-27 | Cyclic diamine compound with 6 membered ring groups |
KR1020037016480A KR100842708B1 (ko) | 2001-06-29 | 2002-06-27 | 6원 환식기를 가지는 환상 디아민 화합물 |
HK04106466A HK1065031A1 (en) | 2001-06-29 | 2004-08-27 | Cyclic diamine compounds bearing six-membered cyclic groups |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/893,697 US6509329B1 (en) | 2001-06-29 | 2001-06-29 | Cyclic diamine compound with 6-membered ring groups |
US09/893,697 | 2001-06-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2003002535A1 true WO2003002535A1 (en) | 2003-01-09 |
Family
ID=25401923
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2002/006489 WO2003002535A1 (en) | 2001-06-29 | 2002-06-27 | Cyclic diamine compounds bearing six-membered cyclic groups |
Country Status (12)
Country | Link |
---|---|
US (1) | US6509329B1 (ja) |
EP (1) | EP1403249B1 (ja) |
JP (1) | JP4235103B2 (ja) |
KR (1) | KR100842708B1 (ja) |
CN (1) | CN1242992C (ja) |
AT (1) | ATE320416T1 (ja) |
CA (1) | CA2451240C (ja) |
DE (1) | DE60209904T2 (ja) |
ES (1) | ES2260438T3 (ja) |
HK (1) | HK1065031A1 (ja) |
TW (1) | TWI236470B (ja) |
WO (1) | WO2003002535A1 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPWO2003002536A1 (ja) * | 2001-06-29 | 2004-10-14 | 興和株式会社 | 非対称環状ジアミン化合物 |
JPWO2003020703A1 (ja) * | 2001-08-30 | 2004-12-16 | 興和株式会社 | 環状アミン化合物 |
WO2005034953A1 (ja) * | 2003-10-10 | 2005-04-21 | Kowa Co., Ltd. | 血管新生抑制薬 |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6632810B2 (en) | 2001-06-29 | 2003-10-14 | Kowa Co., Ltd. | Cyclic diamine compound with condensed-ring groups |
US6432957B1 (en) * | 2001-06-29 | 2002-08-13 | Kowa Co., Ltd. | Piperazine derivative |
WO2004032931A1 (ja) * | 2002-10-11 | 2004-04-22 | Kowa Co., Ltd. | 癌の処置方法 |
WO2004032933A1 (ja) * | 2002-10-11 | 2004-04-22 | Kowa Co., Ltd. | 癌の処置方法 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0774257A2 (en) * | 1995-11-20 | 1997-05-21 | Kowa Co. Ltd. | Use of piperazine and homopiperazine compounds for the inhibition of cellular adhesion and infiltration |
JPH1192382A (ja) * | 1997-09-24 | 1999-04-06 | Kowa Co | 細胞接着阻害剤 |
EP0926138A1 (en) * | 1996-08-23 | 1999-06-30 | Kowa Co. Ltd. | Diamide compounds and drugs containing the same |
EP0934924A1 (en) * | 1996-10-11 | 1999-08-11 | Kowa Co. Ltd. | Novel diamide compounds and drugs containing the same |
US6432957B1 (en) * | 2001-06-29 | 2002-08-13 | Kowa Co., Ltd. | Piperazine derivative |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2000509070A (ja) | 1996-04-30 | 2000-07-18 | ヘキスト・マリオン・ルセル・インコーポレイテツド | 2,6―ジアルキル―4―シリル―フェノールを使用して血管細胞接着分子―1を阻害する方法および慢性炎症性疾患を治療する方法 |
JPH09309877A (ja) * | 1996-05-20 | 1997-12-02 | Teijin Ltd | 環状ジアミン誘導体並びにその製造及び使用 |
JP3577183B2 (ja) | 1996-06-17 | 2004-10-13 | 花王株式会社 | 動脈硬化症予防・治療剤 |
DE19637237A1 (de) * | 1996-09-13 | 1998-03-19 | Merck Patent Gmbh | Piperazin-Derivate |
JPH10147568A (ja) | 1996-11-19 | 1998-06-02 | Mitsui Chem Inc | ナフタレン誘導体およびそれを有効成分として含有する医薬品 |
JPH10182550A (ja) | 1996-12-25 | 1998-07-07 | Mitsui Chem Inc | ヒドロキシ安息香酸誘導体およびそれを有効成分として含有する医薬品 |
JP2000319277A (ja) | 1999-05-11 | 2000-11-21 | Ono Pharmaceut Co Ltd | 縮合ピラジン化合物およびその化合物を有効成分とする薬剤 |
JP4186518B2 (ja) * | 2001-06-15 | 2008-11-26 | アステラス製薬株式会社 | フェニルピリジン誘導体 |
US6552188B2 (en) * | 2001-06-29 | 2003-04-22 | Kowa Co., Ltd. | Unsymmetrical cyclic diamine compound |
-
2001
- 2001-06-29 US US09/893,697 patent/US6509329B1/en not_active Expired - Fee Related
-
2002
- 2002-06-27 DE DE60209904T patent/DE60209904T2/de not_active Expired - Lifetime
- 2002-06-27 ES ES02736188T patent/ES2260438T3/es not_active Expired - Lifetime
- 2002-06-27 JP JP2003508916A patent/JP4235103B2/ja not_active Expired - Fee Related
- 2002-06-27 CA CA2451240A patent/CA2451240C/en not_active Expired - Fee Related
- 2002-06-27 AT AT02736188T patent/ATE320416T1/de not_active IP Right Cessation
- 2002-06-27 KR KR1020037016480A patent/KR100842708B1/ko not_active IP Right Cessation
- 2002-06-27 CN CNB028128214A patent/CN1242992C/zh not_active Expired - Fee Related
- 2002-06-27 WO PCT/JP2002/006489 patent/WO2003002535A1/ja active IP Right Grant
- 2002-06-27 EP EP02736188A patent/EP1403249B1/en not_active Expired - Lifetime
- 2002-06-28 TW TW091114337A patent/TWI236470B/zh not_active IP Right Cessation
-
2004
- 2004-08-27 HK HK04106466A patent/HK1065031A1/xx not_active IP Right Cessation
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0774257A2 (en) * | 1995-11-20 | 1997-05-21 | Kowa Co. Ltd. | Use of piperazine and homopiperazine compounds for the inhibition of cellular adhesion and infiltration |
EP0926138A1 (en) * | 1996-08-23 | 1999-06-30 | Kowa Co. Ltd. | Diamide compounds and drugs containing the same |
EP0934924A1 (en) * | 1996-10-11 | 1999-08-11 | Kowa Co. Ltd. | Novel diamide compounds and drugs containing the same |
JPH1192382A (ja) * | 1997-09-24 | 1999-04-06 | Kowa Co | 細胞接着阻害剤 |
US6432957B1 (en) * | 2001-06-29 | 2002-08-13 | Kowa Co., Ltd. | Piperazine derivative |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPWO2003002536A1 (ja) * | 2001-06-29 | 2004-10-14 | 興和株式会社 | 非対称環状ジアミン化合物 |
JPWO2003020703A1 (ja) * | 2001-08-30 | 2004-12-16 | 興和株式会社 | 環状アミン化合物 |
WO2005034953A1 (ja) * | 2003-10-10 | 2005-04-21 | Kowa Co., Ltd. | 血管新生抑制薬 |
Also Published As
Publication number | Publication date |
---|---|
KR20040015738A (ko) | 2004-02-19 |
EP1403249A4 (en) | 2005-03-16 |
HK1065031A1 (en) | 2005-02-08 |
CN1520400A (zh) | 2004-08-11 |
US6509329B1 (en) | 2003-01-21 |
EP1403249A1 (en) | 2004-03-31 |
KR100842708B1 (ko) | 2008-07-01 |
ES2260438T3 (es) | 2006-11-01 |
DE60209904D1 (de) | 2006-05-11 |
CA2451240A1 (en) | 2003-01-09 |
CN1242992C (zh) | 2006-02-22 |
JP4235103B2 (ja) | 2009-03-11 |
DE60209904T2 (de) | 2006-08-17 |
EP1403249B1 (en) | 2006-03-15 |
ATE320416T1 (de) | 2006-04-15 |
CA2451240C (en) | 2010-02-09 |
JPWO2003002535A1 (ja) | 2004-10-14 |
TWI236470B (en) | 2005-07-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10988456B2 (en) | O-aminoheteroaryl alkynyl-containing compound, preparation method therefor, and use thereof | |
TWI324066B (en) | A pharmaceutical composition for inhibiting cell migration induced by an angiogenic factor | |
JP4220897B2 (ja) | ピペラジン化合物 | |
TW201028393A (en) | Kinase inhibitors and methods of their use | |
WO2003002536A1 (fr) | Compose diamine cyclique asymetrique | |
TW200900058A (en) | N-(heteroaryl)-1-heteroaryl-1H-indole-2-carboxamide derivatives, their preparation and their therapeutic application | |
JP2022515335A (ja) | 置換ピラゾロ[1,5-a]ピリジン化合物、該化合物を含む組成物およびその使用 | |
CN110461853A (zh) | 苯并噻吩雌激素受体调节剂 | |
US20180282327A1 (en) | Method of making tetrahydronaphthyridinyl nonanoic acid compounds | |
JP5243596B2 (ja) | Hdl−コレステロール上昇剤としての3−トリフルオロメチル−ピラジン−2−カルボン酸アミド誘導体 | |
WO2003002535A1 (en) | Cyclic diamine compounds bearing six-membered cyclic groups | |
TWI236469B (en) | Diamine compound with condensed-ring groups | |
US7176199B2 (en) | Aryl-substituted alicyclic compound and medical composition comprising the same | |
JP4276070B2 (ja) | 環状アミン化合物 | |
TW200804330A (en) | Organic compounds | |
WO2003002540A1 (en) | Cyclic diamine compound having five-membered cyclic group | |
MX2010013355A (es) | Nuevos compuestos v. | |
JP5442711B2 (ja) | Hdl−コレステロール上昇剤としての2−トリフルオロメチルニコチンアミド誘導体 | |
TW200536529A (en) | Dosage forms and methods of treatment using VEGFR inhibitors | |
JP2006199656A (ja) | アミド基を有する環状アミン化合物 | |
WO2019189766A1 (ja) | 新規ビアリールアミド誘導体 | |
CN112724134B (zh) | 氮杂吲唑联吡啶衍生物髓细胞增殖抑制剂及其制备方法与在制药中的应用 | |
JPH0543544A (ja) | インドール誘導体およびそれらを有効成分とする抗癌剤耐性克服物質 | |
CN116283918A (zh) | 一种降解受体酪氨酸激酶的双功能化合物及其应用 | |
JP2006182697A (ja) | スルホンアミド基を有する環状アミン化合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2003508916 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020037016480 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2451240 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002736188 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 028128214 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 2002736188 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2004108041 Country of ref document: RU Kind code of ref document: A |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWG | Wipo information: grant in national office |
Ref document number: 2002736188 Country of ref document: EP |